37790 Federal Register / Vol. 65, No. 117 / Friday, June 16, 2000 / Notices

FEDERAL RESERVE SYSTEM

Sunshine Act Meeting

AGENCY HOLDING THE MEETING: Board of

Governors of the Federal Reserve

System.

TIME AND DATE: 10:00 a.m., Wednesday,

June 21, 2000.

PLACE: Marriner S. Eccles Federal

Reserve Board Building, 20th and C

Streets, NW., Washington, DC 20551.

STATUS: Closed.

Matters to be Considered:

1. Personnel actions (appointments,

promotions, assignments,

reassignments, and salary actions)

involving individual Federal Reserve

System employees.

2.Any matters carried forward from a

previously announced meeting.

CONTACT PERSON FOR MORE INFORMATION:

Lynn S. Fox, Assistant to the Board;

202–452–3204.

SUPPLEMENTARY INFORMATION: You may

call 202–452–3206 beginning at

approximately 5 p.m. two business days

before the meeting for a recorded

announcement of bank and bank

holding company applications

scheduled for the meeting; or you may

contact the Board’s Web site at http://

www.federalreserve.gov for an

electronic announcement that not only

lists applications, but also indicates

procedural and other information about

the meeting.

Dated: June 14, 2000.

Robert deV. Frierson,

Associate Secretary of the Board.

[FR Doc. 00–15359 Filed 6–14–00; 11:32 am]

BILLING CODE 6210–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

[60 Day–00–40]

Proposed Data Collections Submitted

for Public Comment and

Recommendations

In compliance with the requirement

of Section 3506(c)(2)(A) of the

Paperwork Reduction Act of 1995 for

opportunity for public comment on

proposed data collection projects, the

Centers for Disease Control and

Prevention (CDC) will publish periodic

summaries of proposed projects. To

request more information on the

proposed projects or to obtain a copy of

the data collection plans and

instruments, call the CDC Reports

Clearance Officer on (404) 639–7090.

Comments are invited on: (a) Whether

the proposed collection of information

is necessary for the proper performance

of the functions of the agency, including

whether the information shall have

practical utility; (b) the accuracy of the

agency’s estimate of the burden of the

proposed collection of information; (c)

ways to enhance the quality, utility, and

clarity of the information to be

collected; and (d) ways to minimize the

burden of the collection of information

on respondents, including through the

use of automated collection techniques

for other forms of information

technology. Send comments to Seleda

Perryman, CDC–Assistant Reports

Clearance Officer, 1600 Clifton Road,

MS–D24, Atlanta, GA 30333. Written

comments should be received within 60

days of this notice.

Proposed Project

Exposure to Aerosolized Brevetoxins

During Red Tide Events—New—

National Center for Environmental

Health (NCEH). Gymnodinium breve is

the marine dinoflagellate responsible for

extensive blooms (called red tides) that

form in the gulf of Mexico. G. breve

produces potent toxins, called

brevetoxins, that have been responsible

for killing millions of fish and other

marine organisms. The biochemical

activity of brevetoxins is not completely

understood and there is very little

information regarding human health

effects from environmental exposures,

such as inhaling brevetoxin that has

been aerosolized and swept onto the

coast by offshore winds. The National

Center for Environmental Health

(NCEH), Centers for Disease Control and

Prevention (CDC) is planning to recruit

100 people who work along the coast of

Florida and who potentially will be

occupationally exposed to aerosolized

red tide toxins some time during the

year following recruitment.

NCEH plans on administering a baseline respiratory health questionnaire

and conducting pre- and post-shift

pulmonary function tests during a time

when there is no red tide reported near

the area. When a red tide develops, we

plan to administer a symptom survey

and conduct pulmonary function testing

(PFT) on a group of study participants

who are working in the area where the

red tide is near shore, and on a control

group of study participants who are not

working in an area where the red tide

is near shore (i.e., are not exposed to the

red tide). We will then compare (1)

symptom reports before and during the

red tide and (2) the changes in baseline

PFT values during the work shift

(differences between pre- and post-shift

PFT results without exposure to red

tide) with the changes in PFT values

during the work shift when individuals

are exposed to red tide. In addition, we

plan to assist in collecting biological

specimens (inflammatory cells from

nose and throat swabs) to assess

whether they can be used to verify

exposure and to demonstrate a

biological effect (i.e., inflammatory

response) from exposure to red tide.

There are no costs to respondents.

Respondents No. of respondents

No. of responses per

respondent

Average burden per response (in

hrs.)

Total burden

Pulmonary History Questionnaire .................................................................... 100 1 20/60 33

Symptom Questionnaire .................................................................................. 100 20 5/60 167

Nasal and throat swabs ................................................................................... 100 20 5/60 167

Pulmonary Function Tests ............................................................................... 100 20 20/60 667

Total .......................................................................................................... ........................ ........................ ........................ 1034

Federal Register / Vol. 65, No. 117 / Friday, June 16, 2000 / Notices 37791

Dated: June 12, 2000.

Kathy Cahill,

Associate Director for Policy, Planning, and

Evaluation, Centers for Disease Control and

Prevention (CDC).

[FR Doc. 00–15253 Filed 6–15–00; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

[Program Announcement 00136]

Landmine Survivor Peer Support

Networks in Five Mine-Affected

Countries; Notice of Availability of

Funds

A. Purpose

The Centers for Disease Control and

Prevention (CDC) announces the

availability of fiscal year (FY) 2000

funds for a cooperative agreement

program for ‘‘Landmine Survivor Peer

Support Networks in Five MineAffected Countries’.

B. Eligible Applicant

Assistance will be provided only to

Landmine Survivors Network (LSN). No

other applications are solicited.

LSN is the most appropriate and

qualified organization for conducting

activities under this program because:

1. LSN has existing staff, both

domestically and internationally,

trained in public health and social

sciences related to landmine survivors.

2. LSN has a significant global

presence, allowing it to coordinate with

local governments and international

organizations in the implementation of

projects related to landmine survivors.

3. LSN has a singularly high level of

expertise and experience in working

with landmine survivor issues.

4. LSN has an existing field presence

including peer support networks in four

of the five countries identified in this

announcement (Bosnia, Ethiopia,

Mozambique and Jordan).

5. LSN has established itself as a

leader in the Non-Governmental

Organization (NGO) community as a

provider of support to individuals,

families, and communities injured by

landmines, giving it the resources and

contacts to implement the program with

the support of professional networks in

the NGO community.

Note: Public Law 104–65 states that an

organization described in section 501(c)(4) of

the Internal Revenue Code of 1986 that

engages in lobbying activities is not eligible

to receive Federal funds constituting an

award, grant, cooperative agreement,

contract, loan, or any other form.

C. Availability of Funds

Approximately $1,200,000 is available

in FY 2000 to fund this award. It is

expected that the award will begin on or

about September 30, 2000 and will be

made for a 12-month budget period

within a project period of up to 3 years.

D. Where To Obtain Additional

Information

Program technical assistance may be

obtained from: Brad Woodruff,

International Emergency and Refugee

Health Branch, National Center for

Environmental Health, Centers for

Disease Control and Prevention, 4770

Buford Highway, NE (F–48), Atlanta,

GA 30341–3724, Telephone number:

770–488–3523, Email address:

baw4@cdc.gov

Business management technical

assistance may be obtained from: Mattie

Jackson, Grants Management Specialist,

Grants Management Branch,

Procurement and Grants Office, Centers

for Disease Control and Prevention,

Room 3000, 2920 Brandywine Road,

Atlanta, GA 30341–4146, Telephone

number: 770–488–2718, Email address:

mij3@cdc.gov

Dated: June 12, 2000.

John L. Williams,

Director, Procurement and Grants Office,

Centers for Disease Control and Prevention

(CDC).

[FR Doc. 00–15251 Filed 6–15–00; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

CDC Advisory Committee on HIV and

STD Prevention: Meeting

In accordance with section 10(a)(2) of

the Federal Advisory Committee Act

(Public Law 92–463), the Centers for

Disease Control and Prevention (CDC)

announces the following committee

meeting.

Name: CDC Advisory Committee on

HIV and STD Prevention.

Times and Dates:

8:30 a.m.–5 p.m., June 29, 2000.

8:30 a.m.–3 p.m., June 30, 2000.

Place: Marriott Atlanta Century

Center, 2000 Century Boulevard NE,

Atlanta, Georgia 30345.

Status: Open to the public, limited

only by the space available. The meeting

room will accommodate approximately

100 people.

Purpose: This Committee is charged

with advising the Director, CDC,

regarding objectives, strategies, and

priorities for HIV and STD prevention

efforts including maintaining

surveillance of HIV infection, AIDS, and

STDs, the epidemiologic and laboratory

study of HIV/AIDS and STDs,

information/education and risk

reduction activities designed to prevent

the spread of HIV and STDs, and other

preventive measures that become

available.

Matters To Be Discussed: Agenda

items include issues pertaining to (1)

national syphilis elimination efforts (2)

strategic planning for HIV Prevention

and (3) CDC’s HIV Prevention efforts in

Africa and India.

Agenda items are subject to change as

priorities dictate.

Contact Person for More Information:

Paulette Ford, Committee Management

Analyst, National Center for HIV, STD,

and TB Prevention, 1600 Clifton Road,

NE, m/s E–07, Atlanta, Georgia 30333.

Telephone 404/639–8008, fax 404/639–

8600, e-mail pbf7@cdc.gov.

The Director, Management Analysis

and Services Office, has been delegated

the authority to sign Federal Register

Notices pertaining to announcements of

meetings and other committee

management activities, for both the

Centers for Disease Control and

Prevention and the Agency for Toxic

Substances and Disease Registry.

Dated: June 12, 2000.

John Burckhardt,

Acting Director, Management Analysis and

Services Office, Centers for Disease Control

and Prevention.

[FR Doc. 00–15252 Filed 6–15–00; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

[Docket No. 00D–1305]

Foods: ‘‘Apple Juice, Apple Juice

Concentrates, and Apple Juice

Products—Adulteration with Patulin;’’

Draft Compliance Policy Guide;

Availability and ‘‘Patulin in Apple

Juice, Apple Juice Concentrates, and

Apple Juice Products;’’ Draft

Supporting Document; Availability

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing the

availability of a draft compliance policy

guide (CPG) entitled ‘‘Apple Juice,

Apple Juice Concentrates, and Apple

Juice Products—Adulteration with